CCM
BIOL

Camber Capital Management’s Biolase, Inc. BIOL Stock Holding History

Camber Capital Management’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-147
Closed -$82K – 51
2015
Q2 		$82K Buy
+147
New +$3.58M 0.01% 43
2015
Q1 		– Sell
-147
Closed -$139K – 47
2014
Q4 		$139K Buy
+147
New +$4.59M 0.01% 43

Other funds holding BIOL

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
TMC
Trellus Management Company Delray Beach, Florida $72.8M AUM 4.5% 1-Year Est. Return
TA
Teton Advisors Rye, New York $142M AUM 42.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Camber Capital Management's BIOL Position: Q4 2017 in Review

Camber Capital Management sold out of Biolase, Inc. (BIOL) in Q4 2017, closing a stake of 427 shares — an estimated $3.21M sold.

Camber Capital Management first reported a position in BIOL in Q3 2013 and held it in 16 quarters. The position peaked at $14.6M in Q4 2014. 24 funds tracked by Wall St. Rank hold BIOL as of Q4 2017.

  • Camber Capital Management reported no remaining Biolase, Inc. position as of Q4 2017 after selling out during the quarter.
  • Camber Capital Management sold 427 Biolase, Inc. shares in Q4 2017, an estimated $3.21M.
  • Camber Capital Management first reported a position in Biolase, Inc. in Q3 2013 and held it in 16 quarters.
  • Camber Capital Management's Biolase, Inc. position peaked at $14.6M in Q4 2014.
  • 24 funds tracked by Wall St. Rank held Biolase, Inc. as of Q4 2017.

Based on Camber Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.